Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ EBITDA Margin

EBITDA as a percentage of revenue.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to -33.3%

EBITDA Margin was -33.3% in Q3 FY2026, down 54.2 pp from a year earlier. On a trailing-twelve-month basis it was 21.0%, up 14.8 pp year over year. Over 3 fiscal years it narrowed by 34.0 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 16 analysts of 43.4% for the fiscal year ending Dec 2026, up from 6.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-33.3%-68.6 pp QoQ
Last fiscal yearDec 2025
6.2%-31.2 pp YoY
LTMSep 2026
21.0%+14.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-54.2 pp+23.4 pp+77.6 pp
1 year-31.2 pp+37.2 pp+68.5 pp
3 years-34.0 pp+49.2 pp+83.2 pp
5 years+44.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
6.2%
Year-over-year change
-31.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 EBITDA Margin of 21.0% is the 7th highest of the 9 companies compared; the peer median is 27.2%.
  • Its year-over-year change of +14.8 pp is the 3rd highest of 8, against a peer median of +0.3 pp.
  • Over three fiscal years its change of -34.0 pp compares with a peer median of +23.5 pp.
JAZZ Competitors Peer median
EBITDA Margin for JAZZ and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202694.3% +118.8 pp+30.5 pp
INCYIncyte CorporationLTM Jun 202635.5% +6.0 pp+16.6 pp
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 202628.8% -5.5 pp-4.2 pp
NBIXNeurocrine Biosciences, Inc.LTM Sep 202625.7% +0.3 pp+7.4 pp
TGTXTG Therapeutics, Inc.LTM Sep 202621.3% -0.4 pp+7673.7 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202621.0% +14.8 pp-34.0 pp
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
Peer median (excluding JAZZ) 27.2%+0.3 pp+23.5 pp

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.09B3.66B3.83B4.07B4.27B
Cost of Revenue440.76M540.52M435.58M445.71M503.3M
Gross Profit2.65B3.12B3.4B3.62B3.76B
Gross Margin85.8%85.2%88.6%89.0%88.2%
Research & Development505.75M590.45M849.66M884M782.74M
Selling, General & Admin1.45B1.42B1.34B1.39B1.81B
Operating Expenses2.48B3.18B2.82B2.91B3.54B
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
EBITDA1.03B1.47B1.45B1.52B262.76M
EBITDA Margin33.2%40.1%37.8%37.4%6.2%
Operating Income170.28M(65.53M)578.58M716.63M224.42M
Operating Margin5.5%-1.8%15.1%17.6%5.3%
Interest Income00000
Interest Expense278.77M288.24M289.44M238.1M195.05M
Other Income / Expenses(283.83M)(317.18M)(283.66M)(247.94M)(853.01M)
Income Before Tax(113.55M)(382.71M)294.92M468.69M(628.59M)
Pre-Tax Margin-3.7%-10.5%7.7%11.5%-14.7%
Income Tax Expense216.12M(158.65M)(119.91M)(91.43M)(272.44M)
Net Income(328.95M)(224.06M)414.83M560.12M(356.15M)
Net Margin-10.6%-6.1%10.8%13.8%-8.3%
EPS (Basic)(5.51)(3.58)6.559.06(5.84)
EPS (Diluted)(5.51)(3.58)6.108.65(5.84)
Weighted Avg Shares59.69M62.54M63.29M61.84M60.98M
Weighted Avg Shares (Diluted)59.69M62.54M72.07M66.01M60.98M

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.